Innovations in Predictive 3D Modeling of Live Human Cells, Vaccine Development, Gene Editing, and Targeted Protein Degradation Platforms

Share this:
Published: 18 May 2018

This edition of the Genetic Technology TOE depicts life sciences trends across predictive 3D modeling of live human cells, vaccine development, gene editing, and targeted protein degradation platforms. The corresponding clinical trials scenario is also covered. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Predictive 3D modeling, live human cells, vaccine development, gene editing, targeted protein degradation platform, artificial intelligence, food allergy, ubiquitin proteasome mechanism, druggable proteins, RNAi drugs, hereditary amyloidosis



Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..